Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy

RegulatoryLu AH69593Positive

AI Analysis

Summary

Lundbeck received FDA Fast Track designation for Lu AH69593, an oral orexin 2 receptor agonist, for treating narcolepsy patients. Fast Track status accelerates development and review of the investigational drug.

Outcome Details

Fast Track designation granted

Importance:6/10

Sentiment:

0.70

FDAFast Trackorexin receptor agonistnarcolepsyregulatory approval

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Pharma on July 23, 2026 7:33 AM

Read Original